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Summary 
The concept of the cellular glycoprotein vitronectin acts as a biological ‘glue’ and key 
controller of mammalian tissue repair and remodelling activity is emerging from nearly 50 
years of experimental in vitro and in vivo data. Unexpectedly, the vitronectin-knock-out 
mouse was found to be viable and to have largely normal phenotype. However, diligent 
observation revealed that the VN-KO animal exhibits delayed coagulation and poor wound 
healing. This is interpreted to indicate that vitronectin occupies a role in the earliest events of 
thrombogenesis and tissue repair. That role is as a foundation upon which the thrombus 
grows in an organised structure. In addition to closing the wound, the thrombus also serves to 
protect the underlying tissue from oxidation, is a reservoir of mitogens and tissue repair 
mediators and provides a provisional scaffold for the repairing tissue. In the absence of 
vitronectin (e.g. VN-KO animal) this cascade is disrupted before it begins. 	  
Our data demonstrates that a wide variety of biologically active species associate with VN. 
While initial studies were focused on mitogens, other classes of bioactives (e.g. 
glycosaminoglycans, metalloproteinases) are now also known to specifically interact with 
VN. Many of these interactions are long-lived, often resulting in multi-protein complexes, 
while others are stable for prolonged periods. Multiprotein complexes provide several 
advantages: prolonging molecular interaction; sustaining local concentrations, facilitating co-
stimulation of cell surface receptors and thereby enhancing cellular / biological responses. 
We contend that these, or equivalent, multi-protein complexes mediate vitronectin 
functionality in vivo. It is also likely that many of the species demonstrated to associate with 
vitronectin in vitro, also associate with vitronectin in vivo in similar multi-protein complexes. 
Thus the predominant biological function of vitronectin is that of a master controller of the 
extracellular environment; informing, and possibly instructing cells ‘where’ to behave, 
‘when’ to behave, and ‘how’ to behave (i.e. appropriately for the current circumstance).  
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Introduction – What is VN? 
An ability to repair damaged tissue(s) is essential to sustain life in all multicellular 
organisms. We remain in awe of the ability of some amphibians (e.g. salamander) and lizards 
to completely regenerate lost appendages with fully restored functionality. The biological, 
physiological and molecular events that underlie tissue repair and regeneration has been a 
focus of human intrigue and experimentation for centuries. However, only recently are we 
beginning to understand how complex this challenge is in higher order organisms, especially 
those with multiple and complex tissue types. It requires a cascade of temporal and spatial 
molecular and cellular events, of which absent or defective function results in reduced 
individual fitness and life expectancy. In this brief review we introduce and discuss the 
emerging concept of the cellular glycoprotein vitronectin as a biological ‘superglue’ and key 
controller of mammalian tissue repair and remodelling.  
Vitronectin (VN) was first described as an adhesive protein that supported the 
attachment and spreading on glass (Latin: vitreous, ‘of glass’) of ‘unadapted’ (primary) cells 
(1). It is the property of serum that enables mammalian cells to adhere to culture vessels, 
supporting cell survival and propagation. Therein lies the first clue to its biological function. 
Since this initial report, VN has been independently “rediscovered” by several investigators 
and was reported variously as ‘serum spreading factor’ (2), ‘S protein’ (of complement, 
equivalent to ‘Protein X’, and not to be confused with ‘Protein S’) (3), Plasminogen activator 
inhibitor-1 binding protein (4), somatomedin B (SMB, 5) and ‘epibolin’ (6). It shares 
structural similarities with the membrane-attack-complex inhibitor (of complement) (7), 
plasminogen activator inhibitor-1 (PAI-1) binding protein (PAIBP) (4) and with the matrix 
metalloproteinase (MMP)-21 (8). Indeed we have used this similarity to MMP and the well-
described hemopexin-like repeats with the solution for the SMB domain to create a new 
model of VN (Figure 1). 
Physico-chemical analysis of VN purified from human tissues indicates that it 
possesses a high degree of conformational flexibility (Fig 1). It is present in vivo as 
monomeric (native) and multimeric (termed ‘denatured’) forms, depending upon its 
association with other molecular species and the activity of proteolytic enzymes, and includes 
conserved structural motifs that confer VN with specialised functions (9; 10). The 44-residue 
N-terminal SMB domain is frequently found as a biologically active cleavage product, 
reported to homodimerise	  and	  bind	  with	  the	  urokinase	  receptor	  (uPAR)	  and	  PAI-­‐1	  (11). 
	  4	   Vitronectin	  –	  Master	  Controller	  or	  Micromanager?	  
	  
In spite of these reports, VN is commonly considered to be an incidental component of the 
extracellular matrix (ECM), primarily associated with endothelial and perivascular tissue. In 
contrast to ‘classical’ ECM glycoproteins such as collagen (COL), fibronectin (FN) and 
laminin, which have structural functions, VN is a ‘matricellular’ protein. Matricellular 
proteins are “modular, extracellular proteins whose functions are achieved by binding to 
matrix proteins as well as to cell surface receptors, or to other molecules such as cytokines 
and proteases that, in turn, interact with the cell surface” (12). Thus while not possessing 
bona fide structural credentials, nonetheless VN is a critical component of the extracellular 
space. 
VN can be detected in most tissues, particularly after exposure to trauma or stress (13). 
Vitronectin is present at high concentrations in the peripheral vasculature (200-400 µg/mL) 
(14), and is synthesised predominantly by hepatocytes in the liver. Given the abundance of 
VN in blood plasma (c.f. FN 300-500 µg/mL) the first decades of VN research were largely 
focused on how VN contributed to homeostasis and innate immunity (15; 16). However, 
recent evidence indicates VN has a wider role consistent with its matricellular activity: 
modulating biological functions critical for the survival of the organism. In this review we 
discuss the functional dependency many endogenous regulatory species have for VN, 
providing evidence that VN should be viewed as a molecular organiser or, micromanager. 
The synthesis of VN by somatic tissues is minimal in comparison to hepatocyte 
production (17). VN is synthesised as a precursor species with limited activity and is 
transported into the interstitial space via receptor-mediated exo- and transcytosis (13, 18). 
Messenger RNA encoding VN (gene VTN, on 17q11.2 [HGNC:12724]) is detectable in most 
cell and tissue types, and its expression is frequently upregulated in tissues experiencing 
stress (e.g. proinflammatory response) (19). When tissue is subjected to stress, 
immunoreactive VN accumulates in the extravascular space. It also accumulates in the 
interstitial space around tumour islands (carcinomas and sarcomas). Deposits of VN are 
notably enriched in immune complexes associated with chronic inflammatory diseases (e.g 
rheumatoid arthritis) and chronic fibrotic diseases (lung, liver and kidney fibrosis) 19). In 
response to acute tissue injury, VN interacts directly with elements of the complement (20) 
and coagulation cascades (21), through which it impacts upon thrombus formation, stability 
of vessel occlusion and subsequent inflammation and immune responses. This activity is 
largely a consequence of circulating in complex with PAI-1 (22). Thus, VN participates in 
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key physiological events that take place during the re-establishment of vascular homeostasis, 
wound repair and tissue regeneration. Confocal microscopy has localised VN to unidentified 
cytoplasmic structures within necrotic cells but it is not found associated with early apoptotic 
cells (i.e. cells with compromised membrane integrity) (23). VN accumulation in sites of 
injury, has been interpreted as leakage from local vessels.  It is conjecture whether VN acts as 
an alarm signal, phagocytic signal (opsonin), immunosuppressant, or has some 
protective/sequestration function in this situation.  
Vitronectin is also associated with a number of ‘solid’ human tumours, in particular 
aggressive and metastatic tumours (24, 25, 26). As evident in traumatised tissue (above), VN 
is frequently enriched in the pericellular stroma, the interstitial boundary evident between 
tumour cell islands/clusters and adjacent ‘normal’ connective tissue (27, 28). Less surprising, 
VN is also found in the walls of tumour-associated blood vessels (29). These observations 
suggest that VN fulfils a key function, as yet uncharacterised, at structure-function 
boundaries. In contrast, ‘normal’ or homeostatic tissues are at best ‘weakly reactive’ for VN. 
In uninjured tissues immunoreactive VN is usually limited to ducts and small blood vessels as 
a homogeneous, weak staining reaction (26).  
 
Structure and Function (monomeric/polymeric) 
The mature VN polypeptide is stabilised by multiple disulphide bonds located at the 
carboxyl polycationic domain and amino SMB terminal domain. It is extensively decorated 
with: (a) saccharides at three N-glycosylation motifs (Fig 1); (b) at least two sulphates on 
tyrosine residues (27); and (c) multiple phosphate groups on threonine residues (28). 
Vitronectin exhibits a high degree of conformational flexibility (9) which presumably is 
determined by the local aqueous environment. Small angle X-ray scattering experiments 
demonstrate that in aqueous phase VN monomers assume a ‘peanut-shaped’ globular 
conformation ~11 nm long and ~5 nm wide (29). In this configuration VN is largely 
unreactive and has little binding affinity towards heparin, presumably because the cell 
recognition RGD and polycationic (heparin-binding) motifs are structurally hindered (Fig 1). 
In non-aqueous environments (e.g. associated with ‘insoluble’ ECM fibrils), functional 
studies suggest VN ‘denatures’ and self-assembles into multimeric meshworks (9). In this 
configuration, previously cryptic functional motifs become available and confer new 
functional attributes to the VN molecule. 
	  6	   Vitronectin	  –	  Master	  Controller	  or	  Micromanager?	  
	  
The human VN monomer is synthesised as a precursor polypeptide of 478 amino acids 
(75 kDa) including a 19-amino acid signal peptide (16) (Fig 1). Polysaccharides account for 
~30% of the mature mass. Additionally, VN is a substrate for the transglutaminases including 
factor XIIIa, allowing its covalent incorporation into fibrin clots and/or ECM (30). In some 
tissues the 44 aa N-terminal fragment is cleaved, releasing the cysteine-rich SMB peptide 
(31). Further processing cleaves the 75 kDa mature protein at amino acid (aa) 379 into 
daughter polypeptides of 65 kDa and 10 kDa, linked by a disulphide bridge. With a core 
polypeptide comprising multiple structural functions residing in four distinct domains (Fig 1), 
interaction with partner molecules, especially glycosaminoglycans (GAGs), confer mature 
VN with dynamic structural flexibility. Unsurprising each conformation supports distinct 
biological activity. The function of VN is determined by, and dependent upon, interactions 
with other species (e.g. divalent cations, GAGs) which induce conformational change and 
self-assembly into heterogeneous multimolecular complexes (9). Protease activity and/or 
physical interactions with ‘target’ species (usually called ligands) cause VN to ‘denature’ and 
refold into a conformation predisposed to increasing the affinity of such interactions (Fig 1), 
and coincidently self-assemble into fibrils forming a heterogeneous meshwork (extracellular 
matrix) with other extracellular glycoproteins (16). The multimeric state further reveals 
previously cryptic sites, dramatically enhancing VN activity. In addition to the 
aforementioned SMB domain, VN includes the conserved consensus cell-recognition motif 
Arg-Gly-Asp (RGD), a flexible connecting region, and two hemopexin-like domains of two 
similar halves, approximately two hundred amino acid residues large formed from a basic 
repetitive unit of 35 ≥ 45 residues connected by a histidine-rich hinge region (32). The 
hemopexin domains are speculated to prevent haem-mediated oxidative stress through 
sequestration (33). A strongly basic region adjacent to the C-terminus (aa 348-379) assembles 
as a groove supporting interactions with molecular species containing polyanionic domains 
(e.g. GAGs, proteoglycans, metabolites) (reviewed in 16). The structural domains present in 
VN are largely responsible for the polyfunctional biological activity evident in experimental 
analyses of this multi-talented extracellular organiser.  
 In the ‘denatured’ conformation, VN interacts with diverse molecular species present 
in the extracellular and interstitial milieu. Complement intermediates C5b-C6, C5b-C7, and 
complement factors C8 and C9 interact directly with the heparin-binding domain of VN 
(Table 1) (7, 34). PAI-1 and fibrinogen (gamma chain) directly associate with unreactive 
circulating plasma VN (21, 35). Perforins produced by cytolytic T-cells interact with the 
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polycationic region. Thus these antimicrobial polypeptides are effectively captured and stored 
within the provisional ECM and coincidently inhibit lytic activity. Proteases critical to the 
coagulation cascade, PAI-I (36), thrombin, TAT III complex (37), fibrinogen (and fibrin), 
collagen I and III, urokinase and proteolytic fragments derived from their activity (e.g. 
angiostatin/plasminogen, anastellin) (reviewed in 13,16) have all been identified to associate 
with multimeric, or denatured VN. Interestingly, and of potential significance, many of these 
interaction are mediated via the glycosaminoglycan intermediates which bind to VN through 
the basic consensus heparin binding groove (residues 348 - 379) in the carboxyl-terminus 
(38).  
Vitronectin participates in the earliest response to tissue trauma. Measured at micromolar 
concentrations in plasma, VN accumulates as complexes with fibrinogen and with PAI-1. 
These interactions stabilise fibrinogen and PAI-1, preventing unintended coagulation and 
fibrinolysis, respectively (39, 40). Upon activation of the clotting and coagulation cascades 
(triggered by exposure to air, debris from damaged cells, or endogenous alarm signals), 
plasma VN undergoes rapid conformational changes, self-assembling into fibrils and 
exposing cell-binding and glycosaminoglycan binding motifs. Multimerisation reveals 
previously cryptic domains/sites dramatically increasing local concentrations of available 
binding sites and precipitating interactions that support the assembly of the heterogeneous 
multiprotein thrombus complex: a fibrillar meshwork of fibrin, fibronectin, von Willebrand 
factor (vWF), complement pathway (e.g. factor XIII), coagulation intermediates (e.g. factor 
VIII) and cell debris (e.g. necrotic cell fragments). While the clot seals the wound (protecting 
underlying tissue from exposure to air) and re-establishes haemostasis, it coincidently 
supports cell-specific survival, cell infiltration and tissue repair as a provisional ECM. Thus 
the clot is both a reservoir of biologically active species and metabolites (41) and a 
provisional ECM. Molecular crowding ensures bioactive species remain at high local 
concentrations, supporting beneficial and/or deleterious physiological processes. Key 
regulators of clot integrity and stability, tissue plasminogen activator (tPA) and urokinase 
plasminogen activator (uPA), attenuate further activation of plasmin from plasminogen 
precursors sustaining clot integrity. Fibrin break-down (fibrinolysis) releases fibrin 
degradation products, some known to act upon thrombin and inhibit further clot formation, 
while others act upon blood vessel growth and permeability (42). 
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VN interacts directly, and indirectly, with a repertoire of extracellular species which 
support diverse biological and physiological functions (summarised in Table 1). While many 
such interactions are predicted from the presence of consensus sequences within the primary 
sequence of VN, a large number of interactions are complex in nature, dependent upon post-
translational modifications (e.g. glycosylation, conformational rearrangements) and less well-
characterised interactions with intermediate species (e.g. glycosaminoglycans, polysulphated 
proteoglycans, argonaute, part of the RNA-induced silencing complex (RISC)(38).  
GAGs are classically thought to function in the main as inert ‘space-filling’ 
molecules. With a net negative charge, GAGs attract cations (e.g. Na+, Ca2+), positively 
charged metabolites and glycoproteins. Their high net charge also attracts and organises the 
surrounding water, resulting in a semi-aqueous ‘hydrogel’ state. GAGs can be viewed as a 
hydrostatic ‘straight-jacket’, which restricts molecular flexibility and maintains order (43, 
44). They also function as intermediates linking unrelated glycoproteins to multimeric VN 
via the polycation groove (45). Thus the pericellular microenvironment, also called 
glycocalyx, is a rich heterogeneous pool of well-ordered proteins, saccharides, lipids and 
metabolites.  Specific cell surface receptor systems translate the composition of this external 
ECM via outside-in ‘feedback’ signalling pathways. VN, for example, is recognised by the 
VN-binding integrins αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and αIIbβ3 (46).  
Why so many ‘VN receptors’? At the very least these distinct receptors suggest 
specialisation and/or divergent functions. VN ligation of integrins and subsequent 
phosphorylation of intracellular targets causes integrins to become clustered in the plane of 
the cell membrane. This aggregation is thought to precipitate the assembly of protein rafts 
comprising integrins, cytoskeletal proteins and signalling molecules, visible as punctate 
patterns under differential interference contrast microscopy and known as focal adhesion 
contacts (47). Ninety percent of cellular phosphoproteins are located within such multiprotein 
rafts at the cell membrane (48). Focal adhesion contacts are interpreted to represent intimate 
cell linkages between elements of the ECM and transmembrane outside-in signalling 
cascades. These signalling cascades ensure the cell response is appropriate to the 
environment. In the context of tissue injury, VN provides a foundation scaffold for both the 
provisional ECM and coincidently facilitates inflammatory and immune cell infiltration and 
coincidently healing somatic tissue. 
	  Vitronectin	  –	  Master	  Controller	  or	  Micromanager?	   9	  
	  
Given the body of experimental evidence demonstrating the earliest responses to 
tissue injury are orchestrated by VN, it came as a surprise to discover mice in which VN 
expression had been ‘knocked out’ developed normally and had normal blood chemistry (45). 
In a series of careful studies Jang et al. (46) subsequently revealed the VN-KO animals suffer 
from delayed healing. Thrombogenesis is decreased and fibrinolysis is increased in the VN-
KO animals, thereby delaying new blood vessel growth and thus wound healing (46). New 
blood vessels that do form are ‘leaky’ due to the loss of vascular endothelial (VE)-cadherin, a 
molecule that mediates strong cell-cell attachment and forms the ‘water-proof’ seal between 
adjacent endothelial cells (47). Macrophage infiltration is also notably reduced, while the 
levels of plasma tPA and uPA remained elevated in VN-KO mice. Thus the resolution of 
inflammation is also indicated to be defective. The molecular basis of this pathology remains 
to be elucidated. 
 
VN in cancer progression  
Upon interacting with cell surface receptors, VN triggers intracellular signalling cascades, 
which affect critical cellular events, including cell attachment, spreading, migration and 
survival (45). Hence, VN occupies a prominent role in tissue repair and homeostatic 
processes. Considering the wealth and diversity of published experimental data, VN might be 
interpreted as the master controller, the organiser who intimately informs the cell what’s 
happening in its immediate microenvironment. Evidence supporting such a key role is also 
implicated by the contribution of VN to the development and progression of cancer. These 
similarities were sufficient to prompt Dvorak (48) to describe cancer as “wounds that do not 
heal”. Mammalian development, wound repair and cancer share extensive common features 
of phenotype, physiology and biochemical systems.  
Through similar interactions with integrins and uPAR, VN is reported to modulate 
cancer metastasis, possibly functioning as a scaffold, or ECM support for tumour cell 
migration during invasion, and/or endothelial cell migration during angiogenesis (24, 26, 49). 
Evidence supporting this concept is the migration of the highly metastatic MDA-MB-231 and 
MDA-MB-435 breast cancer cell lines when assayed in vitro is inhibited when αvβ3 and 
αvβ5 VN-receptors (VN-binding integrins) are blocked with antagonists (50). The αvβ3 and 
αvβ5 integrins are also critical to angiogenesis; required to sustain tumour growth greater 
than 1≤ 2 mm, and subsequent tumour cell dissemination (47, 51). Collectively the weight of 
	  10	   Vitronectin	  –	  Master	  Controller	  or	  Micromanager?	  
	  
in vivo and in vitro evidence overwhelmingly supports a critical role for VN as a foundation 
ECM, or master organiser, supporting somatic tissue repair and cancer progression through 
direct interactions with binding partners which include PAI-I, uPAR and integrins. 
Subsequently, VN supports tumour cell survival and growth indirectly by supporting 
angiogenesis. 
 
VN supports angiogenesis  
In order to survive and thrive all eukaryotic tissues require a blood supply. This is as true for 
tumour cells as it is for somatic tissues. Indeed without vascularisation tumours cannot grow 
beyond 1–2 mm3, due to a lack of oxygen and other essential nutrients (52, 53). Fundamental 
to new blood vessel growth and survival is the endothelial basement membrane. The 
basement membrane provides anchorage through which cell adhesive receptors, including 
integrins, interact and provide the mechanical tension required for blood vessel 
morphogenesis (54). Dynamic remodelling of the endothelial ECM, particularly by 
membrane-type matrix metalloproteinases (MT-MMPs), co-ordinates de novo formation of 
new vessel tubes. Sprouting endothelium aligns and assembles into new tubes with a new 
vascular basement membrane, a specialised ECM that provides anchorage as well as a 
reservoir for cytokines and growth factors that convey specific and specialised signalling 
functions to the developing vessels. Interestingly the VN receptor, αVβ3, is expressed at high 
levels in endothelial cells during angiogenesis (55).	  
Although angiogenesis was not found to be impaired in VN-KO mice, persuasive evidence 
indicates that VN is pivotal to this process. Upon addition of VN receptor antagonists new 
blood vessel growth is effectively stopped during both physiological and tumour 
angiogenesis (55, 56). Conversely VN and fibronectin also provide essential sources of 
endogenous angiogenic peptides (e.g. anastellin) and partner molecules for functional 
multiprotein complexes (e.g. anti-thrombin III) (57).	  
In addition to key angiogenic functions, VN is required to facilitate tumour cell invasion. As 
well as providing a provisional ECM for invading tumour cells, VN localises functional 
MMPs to the tumour-ECM boundary (58). VN-immobilised MMPs cleave adjacent ECM 
species (including VN), allowing tumour cells to penetrate constraining interstitial tissue 
ECM. Further, it facilitates integrin-mediated tumour cell motility (59). Recent evidence for 
the integrin-dependence of ‘cancer stem cells” (CSC) and metastatic dissemination and/or 
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residual disease has been described (60). Notwithstanding, CSC survival and subsequent 
progression remains dependant upon interactions between CSCs and the local 
microenvironment (61).	  
 
VN confounds serum-free tissue culture data  
It is time to re-evaluate and reinterpret our past in vitro studies in terms of our current 
understanding of the informative in vivo pericellular environment, especially when it comes 
to cellular responses to growth factors. Extensive evidence indicates that VN present within 
serum is the primary and the most effective species that supports cell attachment and 
spreading on tissue culture (TC) plastic (62, 63, 64). This is attributed to the fact that at serum 
concentrations of 2%, or greater, VN is the most prominent ECM protein to adsorb onto TC 
plastic, when compared to other ECM proteins such as FN and laminin (65). Interpretation of 
data gained from such in vitro assays invariably fail to account for the competative activity of 
albumin, IgG, alpha-1-antitrypin and other non-adhesive factors present in the serum (66, 67). 
On the contrary, VN outcompetes all of these plasma proteins to adsorb readily to TC plastic 
(68, 69) in the order of 42-55 ng/cm2 (65).  
Until recently, in vitro studies investigating the effects of growth factors on cell 
functions were performed with (a) serum-starved cells seeded in media containing the growth 
factor/s of interest together with at least 0.5 to 2% serum, or (b) on pre-plated cells starved 
from serum for 4-24 hours. In either case, VN adsorbed from serum-containing media (63) 
remains present for the duration of the assay. Thus VN can localise endogenous (serum) 
growth factors more effectively and induce synergistic and/or confounding effects on the 
cells. Interpreting data from such experiments is ambiguous, since it is unclear if the observed 
response(s) is a response to the growth factor (GF), or a response to residual 
GF:VN/GF:ECM associations. Given what we now know, care should be taken when 
interpreting data investigating the effects of growth factors on cell behaviour, especially 
when cells are exposed to even the smallest presence of serum. Hence, the contribution of 
VN and VN-binding integrins should be acknowledged and studied alongside the classical 
growth factor:receptor-mediated effects.  
With this in mind we re-evaluated our in vitro experimental design several years ago. 
We assembled (pre-bound) complexes of mitogen/growth factors and ECM species for our in 
vitro experiments (70, 71, 72, 73, 74). This approach acknowledged the evidence that cells 
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and cell surface ‘receptors’ do not encounter extracellular species in isolation, nor in fluid 
phase. In vivo the pericellular environment is a hydrogel of aqueous water organised by the 
glycocalyx of extracellular GAGs and metabolite polyions (75). In such a constrained 
environment molecular crowding ensures frequent and prolonged interactions are statistically 
favoured, can be sustained, and effectively ensure ‘high’ local concentrations of the 
interacting partners (76). 
Applying this strategy revealed that VN is able to assemble multiprotein complexes 
with a variety of biologically active species. Biochemical characterisation studies of insulin-
like growth factor (IGF)-II were found to be reproducibly ‘contaminated’ with an 
unidentified 70 kDa serum species; later identified as VN (76). At the time, why IGF-II was 
‘contaminated’ with VN when the closely related mitogen, IGF-I was not, could not be 
explained. Subsequent work discovered that IGF-I can also associate with VN, however, only 
via intermediates, select insulin-like growth factor binding proteins (IGFBP) (77).  The most 
surprising aspect of these studies was the observation that in the presence of the VN 
‘contamination’ cellular responses to IGF-II where greater than uncontaminated IGF-II! The 
contaminating VN clearly contributed functional properties that were not induced when it 
was absent. We now recognise that VN acts as a scaffold for IGFs, and several other 
mitogens, and presents bioactive species to cognate cell surface receptors in the context of 
simultaneous interactions with the VN receptor, and potentially other species in vivo (e.g. 
GAGs). This makes sense of observations of molecular rafts within the cell membrane (78) 
that effectively concentrate receptor and signalling pathway components in close proximity, 
dramatically increasing effective signal transduction and cell response. Coactivation of the 
VN receptor and IGF receptor is necessary for the enhanced response.  
	  
VN the master organiser  
To date, most in vitro studies examining VN have employed the ‘solution in a test-tube’ 
approach. This strategy, while simple and convenient, is completely unlike the in situ 
environment in which the experiment occurs. This approach denies processes that take place 
at the molecular scale, that do occur in vivo. For example, the constraints imposed by even 
transient interactions with large ‘insoluble’ structural polymers common in the ECM (e.g. 
collagens) change the dynamics of transit binding events and possibly also induce 
conformational reorganisation. Introduced above, VN responds to interactions with itself 
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and/or unrelated molecular species, including other ubiquitous ECM polymers (fibronectin, 
collagens, fibrin, poly-sulphated proteoglycans, etc.) and charged small metabolites (cations, 
glycopeptides, etc.) with conformational reorganisation. Dynamic responsiveness imparts VN 
with novel functional properties appropriate to the local needs. This property could explain 
the sometimes contradictory and confounding experimental observations present in the VN 
literature. 
The evidence indicating VN primarily functions as a micromanager includes the 
original description of ‘alpha-one protein’ by Holmes (1). Holmes used soda glass beads to 
both isolate VN from human serum and later glass and polystyrene treated with VN to culture 
‘unadapted’ HeLa, human conjunctiva and human heart cell lines for several years (1). Today 
we have replaced glass vessels with plasma-treated polystyrene but still require serum, 
containing substantial concentrations of VN, to support cell attachment and proliferation. As 
mentioned earlier, serum from which VN has been depleted fails to support mammalian cell 
attachment and survival (63, 64, 79). One explanation for this observation is that in the 
absence of VN, the well-described structural components of coagulation (fibronectin, 
fibrinogen, collagens and serine protease zymogens) are insufficient to self-assemble an 
appropriately organised provisional ECM capable of engaging cell attachment systems that, 
in turn, trigger classical ‘outside-in’ signalling cascades (Fig 3) (80, 81, 82). Intriguingly, the 
cell recognition systems that interact with the ECM microenvironment also have the capacity 
to propagate reverse ‘inside-out’ signalling events (82) and cross-talk with diverse unrelated 
transmembrane receptor systems (83, 84, 85). It remains to be established if VN participates 
directly in the molecular events that take place in the ECM, or is it merely a passive scaffold 
structure that organises and micromanages the local hydrogel milieu into appropriate 
functional structures recognised and bound by cell surface receptor systems.  
Throughout this brief review of the ubiquitous extracellular glycoprotein vitronectin, 
we present and discuss experimental evidence suggesting that VN is more than a structural 
molecule; it is a fundamental organiser, or micromanager of the extracellular 
microenvironment. Assembling a functionally integrated, informative and responsive 
structure is essential to mammalian cell and tissue survival. We contend that VN is a 
principle conductor orchestrating many of the essential processes that contribute to cell 
function. We have also highlighted the importance of confounding effects of ECM proteins 
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present in conventional serum-free tissue culture studies and draw attention to the importance 
of re-evaluating these findings in light of the evidence outlined in this brief review. 
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Table 1: Molecular species reported to interact with Vitronectin  
Name of Interactor Experimental Evidence Interaction Reference 
Epidermal growth factor (EGF) In Vitro Direct 86 
Fibroblast growth factor; basic (bFGF) In Vitro Direct 86 
IGF binding protein 2 (IGFBP-2) In Vitro Direct 77 
IGF binding protein 3 (IGFBP-3) In Vitro Direct 77 
IGF binding protein 4 (IGFBP-4) In Vitro Direct 77 
IGF binding protein 5 (IGFBP-5) In Vitro Direct 87 
Insulin-like growth factor II (IGF-II) In Vivo Direct 76 
Tumour necrosis factor receptor superfamily, 11B (TNF-R IIB) In Vivo Direct 88 
Hepatocyte growth factor (HGF) In Vitro Direct 89 
Proopiomelanocortin (POMC, beta endorphin) In Vitro Direct 90 
Transforming growth factor (TGF) beta 1 (TGF β1) In vivo; In vitro Direct 91 
TGF beta 2 (TGF β2) In Vitro Direct 86 
Vascular endothelial growth factor A (VEGF A) In Vitro Direct 86 
Sonic Hedgehog (Shh) In Vitro Direct 92 
Fibrinogen, gamma chain  In vivo; In vitro Direct 21 
Plasminogen activator inhibitor 1 (PAI-1, Serpine 1) In vivo; In vitro Direct 93 
Plasminogen activator receptor, urokinase type (uPAR, CD87) In vivo; In vitro Direct 41 
Gelatinase A/Type IV collagenase (MMP-2, EC 3.4.24.24) In Vitro Direct 94 
Matrilysin (MMP-7, EC 3.4.24.23) In Vitro Direct 95 
Matrix metalloproteinase-26 (MMP-26, EC 3.4.24.1) In vitro Direct 96 
Neurosin (KLK6, EC 3.4.21.B10) In vivo; In vitro Direct 97 
Casein kinase II (EC 2.7.11.1) In vivo; In vitro Direct 28 
Protein kinase C, alpha (EC 2.7.11.13) In Vitro Direct 98 
Protein kinase C, beta 1 (EC 2.7.11.13) In Vitro Direct 98 
Protein kinase C, gamma (EC 2.7.11.13) In Vitro Direct 98 
Integrin beta 1 (CD29) In Vitro Direct 99 
Integrin beta 3 (CD61) In Vitro Direct 99 
Integrin, beta 6  In Vitro Direct 100 
Integrin beta 8  In Vitro Direct 101 
Integrin alpha 8  In Vitro Direct 102 
Plasminogen  In Vitro Direct 103 
Kininogen (Fitzgerald factor) In vivo; In vitro Direct 104 
Amphiphysin1 In Vitro Direct 105 
Angiostatin (plasminogen fragment) In Vitro Direct 103 
Angiopoietin-1 In Vitro Direct 104 
Angiopoietin-2 In Vitro Direct 104 
Anti-thrombin III (AT III, Serpine C1) In vivo; In vitro Direct 105 
Protein kinase A, cAMP-dependent (EC 2.7.11.11) In Vitro Direct 106 
Nectin-3, Poliovirus receptor-related protein (CD113) In Vitro Direct 107 
Nectin-5, Poliovirus receptor (PVR) (CD155) In Vitro Direct 108 
Lacritin  In Vitro Direct 109 
Collagens, α1A, α2A,  In Vitro Direct 110 
SPARC (osteonectin, BM40)  In vivo; In vitro Direct 111 
β-Endorphin In Vitro Direct 90 
Syndecan-1 (CD138) In Vitro Direct 112 
Syndecan-2 (HSPG-1, fibroglycan) (CD362) In Vitro Direct 112 
Syndecan-4 (Amphiglycan) In Vitro Direct 112 
Heparin cofactor II, Prothrombin In vivo; In vitro Complex 113 
Betaglycan (TGFβ-RIII) In Vitro Complex Mol. Endo., 
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2009 (114) 
A disintegrin-like and metalloproteinase with thrombospondin type motif 
(ADMATS2; ADAMTS3) - heparan sulphate proteoglycan (HSPG) In Vitro Complex 115  
IGF-I - IGFBP-2, 3, -4, -5; (IGF-I:IGFBP-2/-3/-4/-5) In Vitro Complex 77 
Fibroblast growth factor 1 - HSPG In Vitro Complex 56 
Interleukins (2, 3, 4, 5, 6, 7, 12) - HSPG In Vitro Complex 116 
Chemokines (C-C motif) - HSPG In Vitro Complex 115 
Granulocyte-Macrophage Colony Stimulating factor (GM-CSF) - HSPG In Vitro Complex 117 
Interferon-γ - HSPG In Vitro Complex 118  
Tumour Necrosis Factor alpha (TNF-α) - HSPG) In Vitro Complex 118  
Integrin alpha V - Integrin, beta 3 (αvβ3)  In vivo; In vitro Complex 119 
Integrin alpha V - Integrin, beta 5 (αvβ5)  In vivo; In vitro Complex 120 
Integrin alpha V - Integrin, beta 6 (αvβ6)  In vivo; In Vitro Complex 100 
Integrin alpha 8 - Integrin, beta 1 (α8β1) In Vitro Complex 102 
Thrombin - Antithrombin III - HSPG In vivo; In Vitro Complex 121 
Plasminogen activator inhibitor 1 - Thrombomodulin In Vitro Complex 122 
Galectin 1 - Thrombospondin I - Fibronectin 1 – Secreted phosphoprotein 1 In Vitro Complex 123 
	  
Legend  
Table 1: Molecular species reported to interact with Vitronectin  
Molecular species (human only) reported to interact with vitronectin in vivo and/or in vitro. 
Species demonstrated to interact directly with vitronectin are listed, and species that interact 
indirectly, via complex formation, are listed and shaded.  
Abbrev. EGF: Epidermal growth factor; bFGF: Fibroblast growth factor, basic; IGFBP: IGF 
binding protein-2; -3; -4; -5; IGF-I: Insulin-like growth factor I; IGF-II: Insulin-like growth 
factor II; TNF-R IIB: Tumour necrosis factor receptor superfamily, 11B; HGF: Hepatocyte 
growth factor; POMC: Proopiomelanocortin (beta endorphin); TGF: Transforming growth 
factor-beta 1; -beta 2: VEGF: Vascular endothelial growth factor; Shh: Sonic Hedgehog; 
PAI-1: Plasminogen activator inhibitor 1 (Serpine 1); uPAR: Plasminogen activator receptor, 
urokinase type (CD87); MMP-2: Gelatinase A/Type IV collagenase; MMP-7; Matrilysin; 
MMP-26: Matrix metalloproteinase-26; KLK6: kallikrein-6, Neurosin; AT III: Anti-thrombin 
III (Serpine C1); PVR: Poliovirus receptor (Nectin-5, CD155); SPARC: SPARC: secreted 
protein acidic and rich in cysteine, osteonectin (BM40); HSPG: Heparan Sulphate 
Proteoglycan; ADMATS: A disintegrin-like and metalloproteinase with thrombospondin type 
motif; TNF: Tumour Necrosis factor.
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Figure 1: Structural domains of vitronectin (predicted tertiary structure).  
	  
The NMR structure of the somatomedin B (SMB) domain (PDB accession ID 2jq8) was 
fused to a homology model of the remainder of the protein generated by the SWISS-MODEL 
repository by overlaying three contiguous residues found in both structures.  This model is 
based upon the crystal structure of pro-MMP1 (PDB accession ID 1su3), with which 
vitronectin shares 12% sequence identity.  After extensive energy minimisation to resolve 
steric clashes, the structure was relaxed in a short 1 ns simulation in explicit water using 
NAMD.  To generate the open conformation, an interactive in vacuo simulation was carried 
out in which only residues 1 to 60 (comprising the SMB domain and the flexible peptide 
linking it to the polyanionic region) were free to move.  The SMB domain was pulled out of 
place using steering forces averaged over residues 1-40, with each atom experiencing a force 
scaled by its atomic mass.  Both structures were then equilibrated in explicit water at 300K 
for 10 ns. 
This model supports the contention that interactions with the SMB domain act to maintain the 
N- and C-terminal domains in a structured state, and that its disruption or removal triggers an 
order-to-disorder transition exposing previously cryptic RGD peptide and HBD recognition 
motifs. 
HBD: Heparin binding domain; TG: Transglutaminase motif; SMB: Somatomedin B domain; 
RGD: Arginine-Glycine-Aspartic acid (cell adhesion motif); G: consensus glycosylation 
motif; P/S: consensus phosphorylation / sulphation motif. 
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